CervoMed Inc. filings document a clinical-stage biotechnology issuer focused on neflamapimod and age-related brain disorders. Form 8-K reports include Regulation FD disclosures, press release exhibits, operating and financial results, and updates on clinical studies such as RewinD-LB in dementia with Lewy bodies, pharmacokinetic work, biomarker analyses, and ALS platform inclusion.
Proxy materials describe shareholder voting matters, board and governance practices, executive compensation, equity awards, and related pay-versus-performance disclosures. The filing record also identifies CRVO common stock on the Nasdaq Capital Market and provides capital-structure, business-development, and financial-position disclosures relevant to CervoMed's drug-development model.
CervoMed Inc. reported a net loss of $7.96M for the quarter ended March 31, 2026, wider than $4.89M a year earlier, as grant revenue from its NIA award dropped to zero and operating expenses rose.
Research and development spending increased to $5.14M, driven by CMC work on neflamapimod and expansion into frontotemporal disorders and recovery-after-stroke programs, while general and administrative costs rose to $2.98M on higher headcount and professional fees.
CervoMed ended the quarter with $12.9M in cash, cash equivalents and marketable securities and an accumulated deficit of $105.7M. Management states there is substantial doubt about the company’s ability to continue as a going concern, as current resources are not expected to fund operations for 12 months without new financing.
CervoMed Inc reports that Morgan Stanley entities hold an 8.0% beneficial ownership stake. The filing attributes shared voting power of 736,624 shares and shared dispositive power of 739,736 shares to Morgan Stanley reporting units. The filing is a joint Schedule 13G/A amendment signed by authorized Morgan Stanley representatives.
CervoMed Inc. is asking stockholders to vote at its virtual 2026 Annual Meeting on June 8, 2026. Items include electing eight directors, ratifying RSM US LLP as auditor for 2026, an advisory vote on 2025 executive pay, and approving Amendment No. 1 to the 2025 Equity Incentive Plan.
Stockholders of record as of April 17, 2026, when 9,258,719 common shares were outstanding, may attend and vote online. The Board, which includes a majority of independent directors, recommends voting in favor of all four proposals. The proxy also outlines governance practices, committee structures, and detailed executive and director compensation.
CervoMed Inc. reported new brain imaging data from its Phase 2b RewinD-LB trial of neflamapimod in dementia with Lewy bodies (DLB), presented at the 2026 AAN Annual Meeting. The analyses showed neflamapimod increased basal forebrain volume and functional connectivity compared with placebo, suggesting disease-related brain changes might be partly reversible.
The company highlights alignment with preclinical work and prior blood biomarker results, supporting the idea that neflamapimod may act on underlying DLB biology rather than just symptoms. CervoMed plans a global, pivotal Phase 3 DLB trial in the second half of 2026, subject to securing sufficient financing.
AWM Investment Company, Inc. amended a Schedule 13G to report beneficial ownership of 405,165 shares (or share-equivalents) of CervoMed Inc., representing 4.2% of the class. The filing explains AWM holds sole voting and dispositive power over those positions through its advisory role to three funds, with a detailed split of 235,126, 68,748 and 101,291 warrants held by the named funds. The amendment was signed on 04/07/2026.
CervoMed Inc. is providing a detailed update on its lead drug candidate neflamapimod for dementia with Lewy bodies (DLB). The company is presenting new MRI analyses from the 159-patient Phase 2b RewinD-LB trial, global regulatory discussions, and a finalized Phase 3 trial design at the 2026 Lewy Body Dementia Association Annual Meeting.
Neflamapimod’s MRI data suggest a potential positive effect on basal forebrain atrophy and functional connectivity, and blood biomarker data (plasma GFAP) appear responsive to treatment. CervoMed plans to initiate a global, pivotal Phase 3 DLB trial in the second half of 2026, subject to available funding, while also highlighting prior Phase 2a and 2b results showing clinical and biomarker signals.
CervoMed Inc. filed a current report describing an investor presentation that has been made available on its website under the “Investors – Events and Presentations” section. Company representatives may use this material, with possible non‑material modifications, in meetings and conferences with investors and analysts.
The company emphasizes that the presentation is summary information meant to be read together with its other SEC filings and public announcements. The information in this report is being furnished under Item 7.01 and is not deemed “filed” for purposes of the Securities Exchange Act, nor incorporated by reference into other filings unless specifically referenced.
CervoMed reported new analyses from its Phase 2b RewinD-LB trial of neflamapimod in dementia with Lewy bodies (DLB). Patients with lower plasma pTau181 levels, indicating fewer with Alzheimer’s co-pathology, showed greater clinical benefit on key measures such as CDR-SB and ADCS-CGIC.
The company will use a plasma pTau181 enrichment cutoff of <21 pg/mL in its planned global Phase 3 DLB trial, aiming to enroll mainly “pure” DLB patients. PK/PD analyses focused on this population support the planned 50mg TID dosing regimen. CervoMed plans to start Phase 3 in the second half of 2026, subject to available funding.
CervoMed Inc. reported fourth quarter and full year 2025 results and highlighted progress for its lead drug neflamapimod in dementia with Lewy bodies (DLB) and other brain disorders. The company reported positive Phase 2b RewinD-LB data and reached alignment with U.S. and global regulators on a planned Phase 3 trial design, formulation, dose, and dosing regimen in DLB.
As of December 31, 2025, CervoMed had approximately $20.9 million in cash, cash equivalents and marketable securities, down from $38.9 million a year earlier, and believes this will fund operations for approximately six months from the date of the release. Grant revenue declined to about $4.0 million in 2025 from $9.7 million in 2024 due to completion of the RewinD-LB trial phases.
Research and development expenses rose to roughly $21.8 million from $18.8 million, driven by manufacturing improvements, batch-related work from RewinD-LB, and new trials in ischemic stroke recovery and primary progressive aphasia. General and administrative expenses increased to about $10.5 million from $9.2 million, and net loss widened to approximately $27.0 million from $16.2 million.